Targeting BRAF V600E in metastatic colorectal cancer

Patients with mCRC BRAF V600E mutated (BRAFm) are generally associated with poor response to chemotherapy and short progression-free survival and overall ...

Targeting BRAF V600E in metastatic colorectal cancer - PubMed

Patients with mCRC BRAF V600E mutated (BRAFm) are generally associated with poor response to chemotherapy and short progression-free survival ...

The Evolving Treatment Landscape in BRAF-V600E–Mutated ...

Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint ...

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence ...

BRAF V600E-mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard ...

Treatment of patients with BRAF V600E -mutated metastatic ...

Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer ( ...

Targeting BRAF V600E in metastatic colorectal cancer - ecancer

BRAF V600E metastatic colorectal cancer patients are usually associated with poor prognosis resulting in poor overall survival.

Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer - EMJ

The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer, and is associated with poor prognosis. This...

Targeting BRAF in metastatic colorectal cancer

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the ...

Management of BRAF-mutant metastatic colorectal cancer: a review ...

One common mutation in CRC is in the BRAF gene (most commonly V600E substitution). This occurs in ∼10% of patients with metastatic CRC (mCRC) ...

Targeting BRAF in metastatic colorectal cancer - ScienceDirect.com

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the ...

Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - NCI

The mutation, called V600E, is found in about 10% of metastatic colorectal cancers and is associated with especially poor outcomes for patients.

European expert panel consensus on the clinical management of ...

Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in ...

BRAF Mutations as Actionable Targets: A Paradigm Shift in the ...

Until recently, the BRAF V600E mutation was not among actionable genes for colorectal cancer. However, recent discoveries have revealed ...

BRAF Mutation Colon Cancer | Know Your Biomarker

Colorectal cancer with the BRAF V600E mutation can be treated with targeted therapy, like combined BRAF inhibitors and MEK inhibitors. BRAF inhibition, combined ...

Molecular profiling of BRAF-V600E-mutant metastatic colorectal ...

The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) ...

Triplet-targeted therapy improves survival for patients with advanced ...

BRAF mutations are estimated to occur in up to 15% of patients with mCRC, with V600E being the most common BRAF mutation and representing a poor ...

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated ...

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 ...

BRAF mutant colorectal cancer as a distinct subset of colorectal cancer

Targeting BRAF in colorectal cancer (CRC)Other Section ... The BRAFV600E mutation has been widely studied in melanoma. In 2011 vemurafenib, a protein kinase ...

A Treatment Evolution Is Underway in BRAF V600E–Mutated mCRC

“Approximately 7% to 10% of patients with [a diagnosis of] metastatic CRC [mCRC] have a specific mutation in the BRAF gene called V600E,” Nina ...

Current Therapeutic Strategies in BRAF-Mutant Metastatic ... - Frontiers

Around 8–12% of patients with advanced colon rectal cancer (CRC) present with BRAF alterations, in particular V600E mutation, which is ...